IIT Roorkee identifies drug for Chikungunya treatment

Researchers at IIT Roorkee have identified Efavirenz, a drug used for HIV, as a potential treatment for Chikungunya. The study shows it can reduce the virus's replication in lab tests and mice models. Chikungunya is a significant health issue in India, with no approved antiviral treatments currently available. The findings suggest Efavirenz could be a viable option, pending further clinical trials. The research, supported by the Indian Council of Medical Research, has been published in a peer-reviewed journal. However, more studies are needed to confirm its safety and effectiveness for treating Chikungunya in patients.